← 返回

肝细胞癌的免疫图景——我们身处何方?

英文原题:The immune landscape of hepatocellular carcinoma-where we are?

查看英文原题

The immune landscape of hepatocellular carcinoma-where we are?

PubMed 2022/09/27(内容时间) Oncol Lett Q3 · IF 2.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝细胞癌(HCC)是全球范围内诊断最常见的癌症类型之一。在经历了十年的停滞之后,最近几种新型化合物已被证明在HCC治疗中有效。由于免疫治疗在一些但并非所有患者中与重要的临床获益相关,因此识别可靠的预测性生物标志物至关重要。由于肝细胞与免疫细胞之间复杂的相互作用高度依赖于肿瘤微环境,肿瘤微环境已被认为是与治疗反应相关的重要因素,目前正在被广泛研究。在这一网络中,应强调几个重要因素。大多数细胞是肝细胞,但也存在成纤维细胞、内皮细胞和免疫细胞。肿瘤浸润白细胞包括几个细胞群体,每个群体都在形成肿瘤环境中发挥作用。其中一些细胞可能具有抗肿瘤作用,而另一些则可能与疾病进展相关。最重要的亚群包括肿瘤相关巨噬细胞、肿瘤相关中性粒细胞和淋巴细胞。

本综述对这些群体进行了描述。免疫反应受免疫检查点分子调控。参与这一检查点过程的最重要分子之一似乎是程序性死亡-1(PD-1)受体,该受体通常在活化的T细胞、自然杀伤(NK)细胞、B细胞和抗原呈递细胞上被诱导表达。另一方面,程序性死亡配体1(PD-L1)由肿瘤细胞、肝细胞和肝星状细胞,以及Kupffer细胞或肝窦细胞表达。配体与受体之间的复杂相互作用依赖于来自微环境的信号,这些信号可导致癌症发展或凋亡。多项研究的证据表明,肿瘤细胞或免疫细胞上 PD-L1 表达水平较高的患者更有可能从检查点阻断治疗中获得有益结果。本综述重点关注有关微环境及其组成部分的基础信息,尤其是免疫系统的参与。

展开英文摘要原文

Hepatocellular carcinoma (HCC) is one of the most common types of cancer diagnosed worldwide. After a decade of stagnation, several novel compounds have recently been shown to be effective in the treatment of HCC. Since immunotherapy is associated with important clinical benefits in some, but not all patients, it is essential to identify reliable predictive biomarkers. As the complex interplay between hepatocytes and immune cells is highly dependent on the tumor microenvironment, the tumor microenviroment has been suggested to be an important factor associated with the response to therapy and is currently being extensively investigated. Within this network, several important factors should be highlighted. Most of the cells are hepatocytes, but fibroblasts, endothelial cells, and immune cells are also present. Tumor-infiltrating leukocytes include several populations of cells and each of them plays a role in forming the tumor environment. Some of these cells may have antitumor effects, whereas others may be associated with the progression of the disease.

The most important subsets include tumor-associated macrophages, tumor-associated neutrophils, and lymphocytes. These groups are described in the present review. The immune response is controlled by immune checkpoint molecules. One of the most important molecules involved in this checkpoint process seems to be the programmed death-1 (PD-1) receptor, which typically is induced on activated T cells, natural killer (NK) cells, B cells, and antigen-presenting cells. On the other hand, programmed death ligand 1 (PD-L1) is expressed by tumor cells, hepatocytes and hepatic stellate cells, and Kupffer cells or liver sinusoidal cells.

Complex interactions between ligands and receptors are dependent on the signals from the microenvironment leading to either cancer development or apoptosis. Evidence from several studies indicates that patients with higher expression levels of PD-L1 on tumor cells or immune cells are more likely to achieve beneficial results from treatment with checkpoint blockers. This review focuses on the basic information regarding the microenvironment and its components, particularly on immune system involvement.

论文信息

作者
Gryziak M、Wozniak K、Kraj L、Rog L、Stec R
单位
Department of Oncology, Medical University of Warsaw, 02-091 Warsaw, Poland.Poland
文献类型
综述
期刊
Oncology letters2022 Nov
原文标识
PubMed 36245826 · DOI 10.3892/ol.2022.13530